SEARCH
Enter your search term below:
Close
Enter your search term below:
WORLD LEADING BUSINESS SUPPORT
iQur is concentrating its therapeutic research and development on a vaccine platform based on exploiting the immune stimulant properties of Hepatitis B core. iQurÕs patented Tandem Core Technology (TCT) relies on the linkage of two HBV core molecules to form a stable backbone that combines to form virus like particles. Insertion of target antigens into the TCT produces a vaccine that combines the immune alert signal provided by the HBV core with targeting of the immune response to the inserted vaccine antigen. This technology can be used to generate immune responses against infectious pathogens including viruses, bacteria and parasites such and malaria, agents used in biodefence, anima pathogens and cancer associated antigens.
Get all the fresh insights first! Stay up-to-date with all the
latest investment news, blogs and all things SETsquared.
Close
Not long to go until @SETsquared_Br's Tech-Xpo 2022! We can't wait to see 16 innovators exhibit & demo their busin… twitter.com/i/web/status/15413…
SETsquared hosted an investment panel discussion for @ShineInnovate LIF Global Programme participants with experts… twitter.com/i/web/status/15403…
It's showcase day! 14 entrepreneurs from @RAEngGlobal's LIF Advance programme, which have been supported by SETsqua… twitter.com/i/web/status/15403…
Amazing session with Kevin Brooks on Next Steps & Funding for our clinical entrepreneurs during Day 4 of @KSSAHSN H… twitter.com/i/web/status/15402…
One day left to help us win the People's Choice Award at the Triple E Awards by @ACEEU_org!
Like & retweet this:… twitter.com/i/web/status/15402…
SETsquared is a partnership between